Nitric oxide (NO) is produced by numerous different cell types, and it is an important regulator and mediator of many processes including smooth muscle relaxation, neurotransmission, and murine macrophage-mediated cytotoxicity for microbes and tumor cells. Although murine macrophages produce NO readily after activation, human monocytes and tissue macrophages have been reported t o produce only low levels of NO in vitro. The purpose of this study was t o determine if stimulated human mononuclear phagocytes produce inducible nitric oxide synthase (iNOS) mRNA, protein, and enzymatic activity. By reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, we show that human monocytes can be induced t o express iNOS mRNA after treatment with lipopolysaccharide (LPS) and/or interferony (IFN-y). By immunofluorescence and immunoblot analyses, we show monocytes and peritoneal macrophages contain detectable levels of iNOS antigen after stimulations with cytokines in vitro. Control monocytes or those cultured with LPS and/or various cytokines have low levels of NOS functional activity as measured by the ability of cell extracts t o convert L-arginine t o L-citrulline, and they produce low levels of the NO catabolites nitrite and nitrate. Peritoneal macrophages have significantly enhanced nitritehitrate N ITRIC OXIDE (NO) is produced by numerous different cell types, and it is an important regulator and mediator of numerous processes including smooth muscle relaxation, neurotransmission, and murine macrophage-mediated cytotoxicity for microbes and tumor cells."' Murine macrophages express high levels of inducible nitric oxide synthase (iNOS) mRNA and protein after stimulation with various agents such as lipopolysaccharide (LPS) and cytokines (including interferon-y [IFN-y], interleukin-l [IL-l], and tumor necrosis factor [TNF]), and they convert L-arginine to NO and L-citrulline. Although normal human hepatocytes, chondrocytes, and cells of the human colon tumor cell line DLD-I can express iNOS mRNA and produce high levels of NO after treatment with various cytokines and LPS,4-8 we The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section l734 solely to indicate this fact. This is a US government work. There are no restrictions on its use. and others have reported that human mononuclear phagocytes (monocytes, peritoneal macrophages, and alveolar macrophages) produce no or little NO after various treatments in ~i t r o .~"~ Some investigators have noted that human mononuclear phagocytes can be induced to produce modest levels of NO in v i t r~. '~.~~ The purpose of the present study was to determine if stimulated human mononuclear phagocytes produce iNOS mRNA, protein, and enzymatic activity. Results demonstrate that human monocytes and macrophages express iNOS mRNA and protein under certain circumstances in vitro, but they produce only low levels of NO in vitro. The basal levels of nitritehitrate production and NOS activity of monocytes are not changed by treatments with LPS rf: IFN-y, but those of peritoneal macrophages are significantly elevated by these treatments. Although human mononuclear phagocytes do not contain the cofactor tetrahydrobiopterin, increasing tetrahydrobiopterin levels does not enable them to produce high levels of NO.
Nitric oxide (NO) is produced by numerous different cell types, and it is an important regulator and mediator of many processes including smooth muscle relaxation, neurotransmission, and murine macrophage-mediated cytotoxicity for microbes and tumor cells. Although murine macrophages produce NO readily after activation, human monocytes and tissue macrophages have been reported t o produce only low levels of NO in vitro. The purpose of this study was t o determine if stimulated human mononuclear phagocytes produce inducible nitric oxide synthase (iNOS) mRNA, protein, and enzymatic activity. By reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, we show that human monocytes can be induced t o express iNOS mRNA after treatment with lipopolysaccharide (LPS) and/or interferony (IFN-y). By immunofluorescence and immunoblot analyses, we show monocytes and peritoneal macrophages contain detectable levels of iNOS antigen after stimulations with cytokines in vitro. Control monocytes or those cultured with LPS and/or various cytokines have low levels of NOS functional activity as measured by the ability of cell extracts t o convert L-arginine t o L-citrulline, and they produce low levels of the NO catabolites nitrite and nitrate. Peritoneal macrophages have significantly enhanced nitritehitrate N ITRIC OXIDE (NO) is produced by numerous different cell types, and it is an important regulator and mediator of numerous processes including smooth muscle relaxation, neurotransmission, and murine macrophage-mediated cytotoxicity for microbes and tumor cells."' Murine macrophages express high levels of inducible nitric oxide synthase (iNOS) mRNA and protein after stimulation with various agents such as lipopolysaccharide (LPS) and cytokines (including interferon-y [IFN-y], interleukin-l [IL-l], and tumor necrosis factor [TNF] ), and they convert L-arginine to NO and L-citrulline. Although normal human hepatocytes, chondrocytes, and cells of the human colon tumor cell line DLD-I can express iNOS mRNA and produce high levels of NO after treatment with various cytokines and LPS,4-8 we production and NOS activity after treatment with LPS and/ or IFN-y, whereas monocyte nitritehitrate production and NOS activity are not altered by the treatments. Monocytes cultured with various live or heat-killed bacteria, fungi, or human immunodeficiency virus (HIV)-1 do not produce high levels of nitritehitrate. Antibodies against transforming growth factor+ (TGF-P), a factor known t o inhibit iNOS expression and NO production in mouse macrophages, do not enhance NO production in human monocytes or macrophages. Biopterin, an obligate cofactor of iNOS enzymatic activity, is undetectable in freshly isolated or cultured human monocytes and peritoneal macrophages. However, replenishment of intracellular levels of tetrahydrobiopterin by culture with the cell-permeable, nontoxic precursor sepiapterin does not enhance the abilities of the human mononuclear phagocytes t o produce NO in vitro. Mixing experiments show no evidence of a functional NOS inhibitor in human mononuclear phagocytes. Thus, we demonstrate that human mononuclear phagocytes can produce iNOS mRNA and protein, and (despite this) their abilities t o generate NO are very low. This is a US government work. There are no restrictions on its use.
and others have reported that human mononuclear phagocytes (monocytes, peritoneal macrophages, and alveolar macrophages) produce no or little NO after various treatments in ~i t r o .~"~ Some investigators have noted that human mononuclear phagocytes can be induced to produce modest levels of NO in v i t r~. '~.~~ The purpose of the present study was to determine if stimulated human mononuclear phagocytes produce iNOS mRNA, protein, and enzymatic activity. Results demonstrate that human monocytes and macrophages express iNOS mRNA and protein under certain circumstances in vitro, but they produce only low levels of NO in vitro. The basal levels of nitritehitrate production and NOS activity of monocytes are not changed by treatments with LPS rf: IFN-y, but those of peritoneal macrophages are significantly elevated by these treatments. Although human mononuclear phagocytes do not contain the cofactor tetrahydrobiopterin, increasing tetrahydrobiopterin levels does not enable them to produce high levels of NO.
MATERIALS AND METHODS

Cells and culture.
Human blood monocytes and peritoneal macrophages were obtained from normal donors and from women undergoing laparoscopic investigations for infertility as described earlier.n-29 Purity of the monocytes and macrophages after centrifugation and adherence with ~a s h i n g~"~~ was 92% to 98% for monocytes and 95% to 100% for macrophages. In peritoneal macrophages, there was no platelet contamination, whereas in monocyte preparations, there were one to five platelets per monocyte. in Some instances, blood monocytes were purified by elutriation3"; these cells had no platelets. Most cultures were done in Dulbecco's modified Eagle medium (DMEM; without phenol red), and in selected experiments in RPMI-1640 (without phenol red) (Hyclone, Logan, UT). DMEM contained 438 pmol/L L-arginine, and RPMI-1640 contained 870 pmoVL Larginine. In most experiments, the media contained 100 U/mL penicillin and 100 pg/mL streptomycin, but in selected experiments, the media contained no antibiotics. Fresh human serum was prepared in our laboratory from normal donors, and it was used for all human cells (either unheated or after heating for 30 minutes at 56*C), and 10% heated fetal bovine serum (Hyclone, Logan, UT) was used for the cultures with mouse J774 cells. The media and sera were of very low LPS content as determined by testing the chromogenic assay using Limulus amebocyte lysate (Whittaker Bioproducts, Walkersville, MD).
Measurements and assays. Nitrite and nitrate were measured spectrophotometrically as noted Nitrate was converted to nitrite for measurement by use of nitrate reductase supplied by Pseudomonas oleovoruns as noted earlier. 32 The conversion of Larginine to L-citrulline was done as noted earlier using radiolabeled L-arginine." Briefly, cell extracts from mouse 5774 cells and human mononuclear phagocytes were done by three to five freeze-thaw cycles in distilled water containing 100 pmol/L phenylmethylsulfonyl fluoride, 5 pg/mL aprotinin, l pg/mL chymostatin, and 5 pg/ mL pepstatin A. Lysates were collected after centrifugation, and assayed for protein and NOS activity. The assay buffer contained 50 mmol/L HEPES (pH 7.5), 200 pmol/L nicotinamide adenine dinucleotide hydride (NADPH), 1 mmol/L dithiothreitol, 10 pmoU L flavin adenine dinucleotide (FAD), 100 pmol/L tetrahydrobiopterin, and IO pmoVL L-arginine. We used L-arginine labeled with I4C in the guanido position (product number NEC-453, New England Nuclear, Wilmington, DE). Thirty microliters of sample was used in a total reaction mixture of 50 microliters. Samples were done in duplicate or triplicate. Measurement of L-citrulline by lack of adherence to Dowex AG 50W-X8 cation exchange resin (from BioRad, Hercules, CA) correlated with determination of L-citrulline using high-performance liquid chromatography (HPLC)."
Northern analysis of mRNA was done as noted before:' using a cDNA probe specific for human iNOS [bases no. 1992 through 2741 with numbering according to the work of Sherman et The RNAse protection assay was done as noted before.33 We used a probe that was a 512 nucleotide antisense transcript of the human iNOS from the human colon adenocarcinoma cell line DLD-I (bases 610 through 1121): For the reverse transcriptase-polymerase chain reaction (RT-PCR) assays, polyadenylated RNA was extracted from the cells, reverse transcribed into DNA, and then amplified by PCR techniques using iNOS-specific primers designed from sequences of mouse macrophage iNOS4 or human chondrocyte iNOS? The sense primer was (position no. 1975) CAG GAG GAT GCC 7TC CGC AGC TGG (no. 19981, and the antisense was the reverse complement of (no. 2701) ATG ATG AGG TAG TCG AGG AGG GTC (no. 2724), with numbering according to the work of Lyons et The underlined nucleotides signify mouse-human mismatches. RT-PCR products were examined by Southern analysis using a probe specific for human iNOS [bases no. 1992 through 2741 with numbering according to the work of Sherman et d7]. cDNA sequencing was done as noted earlier. 35 Tetrahydrobiopterin content was measured by HPLC.36.37 Briefly, cell pellets and media samples were collected and stored at -70°C until analysis. One hundred microliters of 0.55 m o w HClO, containing 1% iodine and 2% potassium iodide (KI) was added to cell pellets containing 1 to 2 million cells. Ten microliters 5.5 moIL HCIO, containing 10% iodine and 20% K1 was added to 100 pL of media samples. After mixing thoroughly, all of the samples were allowed to stand 1 hour at room temperature. Ascorbic acid, 10 hL of a 10% solution, was then added, and the solutions were neutralized with 60 pL of 1 N NaOH. Triethanolamine HCI buffer, 100 pL of 0.1 morn, pH 8.0 containing 2 mmol/L EDTA, was added with 2 U of Escherichia coli alkaline phosphatase. The solutions were allowed to stand overnight in the dark to dephosphorylate completely. The dephosphorylated solutions (20 to 50 pL) were analyzed directly by high pressure liquid c h r~m a t o g r a p h y .~~,~~ Dephosphorylation did not change biopterin or media neopterin. The limit of detection in this assay for cellular biopterin was 0.1 pmol/million cells, and 5 nmolL for medium biopterin. Not all biopterin samples were verified to be tetrahydrobiopterin; however, when representative samples were analyzed for percent reduction via base oxidation, tetrahydrobiopterin was found to 285% of the total biopterin detected.
Indirect immunofluorescence analysis of monocytes adherent to plastic in LabTek chambers (Naperville, IL) was done as noted earlier3* using a mouse monoclonal antimouse macrophage iNOS from Transduction Laboratories (San Diego, CA). This is an IgG antibody against a 21-kD protein fragment corresponding to amino acids 961 through 1144 of mouse iNOS. It has 78% identity and 85% similarity to human hepatocyte, chondrocyte, and DLD-I iNOS. Immunoblot analysis of cell extracts was done as described earlier:' using the enhanced chemiluminescence (ECL) technique according to the manufacturer's instructions (Amersham, Arlington Heights, IL) . ently accumulate as dead-end NO formation by mouse macrophages is greatest after stimulation with cytokines (eg, IFN-7) and LPS. Analysis of monocytes and peritoneal macrophages from an occasional human donor showed NO (nitritehitrate) production, which was enhanced by LPS ? IFN-y (Fig 1 A) . However, cells from most people did not. When experiments from all individuals were analyzed in aggregate (Fig l , B-E) , it was apparent that human mononuclear phagocytes had very low production in comparison to that of mouse macrophages (Fig I , B and C) . (Fig 1, D and E). However, there was a statistically significant enhancement of nitritehitrate production by peritoneal macrophages by LPS ? IFN-7 (Fig IE) . Analysis of the extracts from cells for their ability to convert L-arginine to L-citrulline showed high level activity in mouse 5774 cells, while human monocytes and peritoneal macrophages had much less activity (Fig 2, A and B) . LPS and LPS/IFN-y treatment caused increases in NOS activity: these increases were statistically significant in mouse 5774 macrophages and human peritoneal macrophages, but not in human monocytes. In separate experiments (results not shown), we showed that N"-monomethyl-L-arginine (2000 pmol/L) inhibited more than 90% of the nitritehitrate production by mouse cells and more than 90% of the ability of mouse and human cells to convert L-arginine to L-citrulline.
RESULTS
Cells
This general low level NO production by human monocytes and human pcritoneal macrophages was found under numerous different culture conditions, and after stimulation with numerous different agents. The following culturc conditions did not render the nlonocytcs or macrophages capable of producing high lcvcls of nitrite-nitrate: culturc in diffcrent amounts or different typcs of sera 13% to 40% (vollvol) human, fetal bovine. and dog serum-heated or unheated]:
culture for 3 to 30 days to allow maturation of the cells with subsequent addition of cytokines and LPS: culture in low oxygen atmosphere (3% oxygen-92% nitrogen with SO CO,.
instead of 95% air with 5% CO?), culture i n medium with excess L-arginine (4.000 pmol/L L-arginine), or culture with 2 mmol/L NADPH. Comparable results with reference to nitritehitrate formation were obtained when using either DMEM or RPMI-1640. and when analyzing blood monocytes isolated hy sequential ticoll-Hypaque-PercoII-adhcrence steps or by elutrirrtion. Table I summarizes results of experiments using different known activators for macrophage functions. These agents have been noted t o activate mouse or human mononuclear phagocytes for a variety of functions. including enhancement of NO production. None of the treatments and culture conditions induced the human mononuclear phagocytes to producc nitritchitratc levels above baseline (control) levels.
Denis"' has noted that after incubation of monocytes with TNF and GM-CSF, Mycoberctrrir~m crvirtm intrrccellrtlnre (complex) causes these monocytes to produce NO. We tested Tetrahydrobiopterin is a necessary cofactor for NOS activity." Others have noted that while mouse macrophages can synthesize tetrahydrobiopterin. human monocytes synthesize none or very littlc:L"..'5 This lack of tetrahydrobiopterin production is because of low levels of the second enzyme in the tetrahydrobiopterin biosynthetic pathway (pyruvoyl-tetrahydrobiopterin ~ynthase)'~.'' in hunlan cells. We found that None of the individuals agents or combinations of agents induced an increase in supernatant media nitritehitrate levels above control levels of 5 to 10 pmol/L. In all experiments except those with PMA, A23187, ConA, and PHA, cultures were done with and without 20 to 200 pmol/L sepiapterin (to assure adequate levels of tetrahydrobiopterin). All experiments were done at least two times; several were done > l 5 times with separate donors. The cells were cultured for 3 to 4 days, and supernatant media were analyzed for nitritehitrate content. All reagents were present throughout the culture period. The following doses were analyzed: LPS, 0.01 to 10 pg/mL; IFN-y, 200 or 500 U/mL; GM-CSF, 500 U/mL; IL-la, 200 U/mL; IL-2, 20 or 100 U/mL; IL-4, 200 or 500 U/mL; IL-6, 200 U/mL; IL-7, 10 or 100 ng/mL; 125 dihydroxyvitamin D, (D,), 5, 25, or 125 nmol/L; PMA, 1. 100, or 200 nmol/L; A23187, 5 pmol/L; conA, 2 or 10 pg/mL; and PHA, 1 or 5 pg/mL.
Abbreviations: PMA, phorbol myristate acetate; conA, concanavalin; PHA, phytohemagglutinin.
freshly isolated human monocytes and peritoneal macrophages contained no measurable tetrahydrobiopterin (Fig 3) . However, both cell types contained neopterin. Although the more differentiated peritoneal macrophages appeared to have higher levels than blood monocytes, the difference was not statistically significant. When monocytes were cultured in vitro with LPS or IFN-y for 3 to 4 days, they still had no measurable tetrahydrobiopterin, but (as expectedJX), their Neopterin or Biopterin (pmollmillion cells) Fig 3 . Neopterin and biopterin content in freshly-isolated human blood monocytes and peritoneal macrophages. Cells were isolated and then cell-associated neopterin and biopterin were measured. Biopterin was undetectable in all samples. The displayed values are the means, and the error bars show one SEM. The difference between the levels of neopterin in peritoneal macrophages and blood monocytes is not statistically significant (P> .05 by Mann-Whitney U test). (Fig 4A) . Addition of the nontoxic, cell-permeable tetrahydrobiopterin precursor sepiapterin to cultures increased cellular tetrahydrobiopterin levels, and decreased neopterin levels (Fig 4B) . Comparable changes in tetrahydrobiopterin and neopterin levels have been observed by others.'l" The decreased neopterin production likely resulted from a combination of the inhibition of GTP cyclohydrolase I enzyme by pterins (both sepiapterin and tetrahydrobiopterin"), and by protein synthesis inhibition of guanosine triphosphate (GTP) cyclohydrolase I by this treatment.Jy Mouse 5774 macrophages contained tetrahydrobiopterin (Fig 5A) , while human monocytes did not (Fig 5B) . Adding sepiapterin to the cultures increased tetrahydrobiopterin levels in both mouse cells and human mononuclear phagocytes (Fig 5 , A and B) . Despite this normalization of tetrahydrobiopterin levels, the human cells still did not produce high levels of nitritehitrate (Fig 5 , C and D) .
levels of neopterin increased after incubation with IFN-y
TGF-P reduces NO production by mouse macrophages ( I ) by enhancing iNOS mRNA degradation, (2) by reducing protein translation from iNOS mRNA, and ( 3 ) by enhancing iNOS protein degradation.5" To determine if the human mononuclear phagocyte-produced TGF-0 was inhibiting iNOS expression and NO production, we cultured monocytes with amounts of chicken IgG against human TGF-01 that would neutralize 100% of the TGF-PI activity, or with normal chicken IgG. Supernatant media from control monocytes, and those treated with I yglmL LPS, 500 U/mL IFNy , or LPS with IFN-y had less than 5 pmol/L nitritehitrate, and this was not altered by the presence of 1 or 10 pglmL anti-TGF-01 Ig or 10 pg/mL of control chicken IgG.
It has been noted that treatment of mouse macrophages with cytokines and LPS increases the steady state content of mRNA for iNOS to levels consistent with the induced high levels of NO prod~ction.~' Genes for the three classes of nitric oxide synthases (constitutive neuronal NOS, constitutive endothelial cell NOS, and inducible NOS) have been cloned, sequenced, and analyzed. For humans, iNOS has been characterized for chondrocytes; hepatocytes,' and a colon cancer cell line.' When mRNA from stimulated mouse 5774 cells and human DLD-1 colon cancer cells were examined by Northern analysis, we noted high levels of induced mRNA; however, by use of northern analysis, we could never detect iNOS mRNA in human control monocytes and those treated with LPS, IFN-y, or LPS with IFN-y (data not shown). When we used the more sensitive RNAse protection assay, we could detect mRNA for iNOS in stimulated human DLD-1 cells, but none could be found in monocytes treated with a variety of different stimuli (Fig 6A) . In our experiments, this protection assay can detect levels of iNOS mRNA in DLD-1 human colon cancer cells in as little as 0.1 pg of total cellular RNA per reaction.
We next used RT-PCR techniques to analyze expression of iNOS mRNA in human monocytes and peritoneal macrophages. By use of this more sensitive technique, we were able to detect iNOS mRNA in human mononuclear phagocytes. After isolation (before adherence to plastic), there was no (or very little) expression of the iNOS mRNA (data not shown). Culture of the cells with LPS and/or IFN-y for 8 hours caused increased expression of iNOS mRNA (Fig 6B) . On southern analysis of the RT-PCR DNA using an iNOSspecific cDNA probe, there was a band at the predicted size of 749 bp. Time course analysis of mRNA expression showed maximum expression after 6 to 8 hours stimulation, with a waning in culture noted at 24 to 36 hours. We found comparable results when we studied monocytes isolated by gradient separation or elutriation, and peritoneal macrophages. This indicates that platelet iNOS52.53 probably did not contribute to our findings, because the elutriated monocytes and the peritoneal macrophages were platelet-free. Although the RT-PCR assays are qualitative or semiquantitative, it appeared that the human phagocytes produced much lower levels of iNOS mRNA than did the mouse 5774 cells and the human DLD-1 colon cancer cells. Based on the sensitivity of the RNAse protection assay, the level of mRNA noted in these experiments was at least 100-fold less than that capable of being found in the RNAse protection assay (see above). We sequenced cDNA derived from the RT-PCR and demonstrated that bases 568 through 3459 were identical to sequences for human chondrocyte, hepatocyte, and colon cancer line DLD-l iNOS cDNA!.~.* We were unable to amplify cDNA from 1-567 in experiments using a variety of primers based upon 5' sequence of human DLDl iNOS. Thus, it is possible that there are sequences in this region of the human monocyte iNOS mRNA that are uniquely different from that of other iNOSs.
When analyzed by indirect immunofluorescence using a mouse monoclonal anti-iNOS antibody, we noted that mouse 5774 macrophages treated for 3 days with IFN--y or LPS with IFN-y had increased numbers of cells reacting with the antibody (Fig 7) . Also, human monocytes treated for 3 days with IFN-y contained antigen that reacted with the antibodies, whereas control cells and those treated with LPS or LPS with IFN-7 did not (Fig 8) . Immunoblot analysis of human monocytes and peritoneal macrophages showed iNOS antigen detected by a mouse monoclonal anti-iNOS antibody (Fig 9) . In control monocytes and peritoneal macrophages cultured for three days, there was very little reactivity. Treatment of the cells for 3 days with LPS ? IFN-./ caused appearance of a band at approximately 130 to 133 kD molecular mass; this band corresponded well with the major immunoreactive material seen in extracts of activated mouse 5774 and RAW macrophages, as well as in activated human DLD-1 colon cancer cells. The presence of an appreciable amount of iNOS protein (antigen) that has little ability to produce NO suggests either a nonfunctional enzyme protein, lack of a cofactors, or existence of an enzyme inhibitor. In an at- tempt to find a functional iNOS inhibitor in human mononuclear phagocytes, we mixed extracts from 5774 cells treated with LPS and IFN-y with equal amounts of extracts from human monocytes (control cells, and those treated with I pg/mL LPS, 500 units/mL IFN-y, or LPS with IFN-7). We found no inhibition of the iNOS enzyme activity of 5774 cells (conversion of I4C-L-arginine to 14C-citrulline) by human monocyte extracts.
DISCUSSION
Although some investigators have been unable to show NO production by human monocytes or macrophages,""s others have noted induction of only low to modest levels of NO In our work reported here, we too are unable to find high level NO production despite finding iNOS mRNA and protein in the human mononuclear phagocytes.
We show that human blood monocytes and tissue (peritoneal) macrophages cultured under a variety of conditions with several different combinations of cytokines, growth factors, and microbial stimulants produce only low levels of NO. Peritoneal macrophages have a statistically significant small increase in NOS activity and NO production after treatment with LPS 2 IFN-y, whereas monocytes do not. Although the level of in vitro NO production by human mononuclear phagocytes we show here is low compared with that produced by mouse macrophages in vitro, this low level production could cause functional changes in cells, especially if NO were generated in areas where volumes are limited (eg, within the vacuolar system or in areas of phagocyte-target cell ~ontact).'~ Vodovotz et alss have noted that mouse peritoneal macrophages incubated with IFN-y and LPS, though initially producing iNOS protein and NO, eventually with time in culture have a posttranslational and nondegradative inactivation of the enzyme. These cultured cells with inactivated enzyme are somewhat comparable with what we see with human mononuclear phagocytes-cells expressing iNOS mRNA and containing iNOS antigen with appropriate levels of iNOS cofactors, but lacking ability to produce NO. They noted that the inactivation of mouse macrophage iNOS required the presence of LPS." Also, exposure of mouse macrophages to low amounts of LPS before treatment with I F Ny has been noted to block expression of iNOS.s6 In our system, we think that LPS is not causing inactivation of iNOS or preventing expression of iNOS because IFN-y alone induced iNOS, and because LPS contamination was minimal (not detectable by limulus testing).
We cannot fully explain the differences in NO production by human and mouse mononuclear phagocytes. Because the same detection systems for NO (measurement of nitrite and nitrate, and conversion of radioactive L-arginine to L-citrulline) were used for both mouse and human cells, it is unlikely that the differences are related to the assays. One unlikely possibility is that human (unlike mouse) mononuclear phagocytes have the capability to metabolize nitrite and nitrate to products undetectable in our assay. Lack of iNOS cofactor activity in human mononuclear phagocytes is a possibility, with deficiency of tetrahydrobiopterin the most likely candidate, because we and other^'^^'''^^^,^' find no detectable biopterin in human monocytes or macrophages. However, raising biopterin levels by addition of sepiapterin does not correct this problem. Other investigators have found comparable results.I4 If human mononuclear phagocytes express functional iNOS activity, they must derive tetrahydrobiopterin from other cells capable of synthesizing it.
Addition of NADPH or the calcium ionophore A23 187 to the cultures of human mononuclear phagocytes also did not enhance NO-producing abilities. Likewise, enzymatic assays of lysates of the human cells in the presence of added NADPH, tetrahydrobiopterin, dithiothreitol, FAD, and Larginine showed no or relatively little activity. Because Vallance et al'* had noted the presence of an arginine derivative in urine and plasma of patients with renal failure that inhibited NOS action, we postulated that human monocytes might contain a comparable inhibitor. However, in our experiments adding excess L-arginine (which should overcome such an inhibitor) did not enhance NO production, and extracts from the human monocytes did not inhibit NOS activity of mouse macrophage extracts. Although we detected monocyte iNOS mRNA production, the levels appeared to be lower than those seen in mouse macrophages. Thus, the reduced levels of NO production could simply be related to an overall lower level mRNA transcription. We were not able to sequence the 5' end of the cDNA from human monocytes, but of that sequenced, there was identity to bases 568 through 3459 of human DLD-1 iNOS cDNA. We noted that the apparent molecular mass of human monocyte iNOS was comparable with that of mouse iNOS and human DLD-l cell iNOS. It is possible that there are cell lineage-specific differences in the 5' region of the mRNA between human monocyte iNOS and human hepatocyte, chondrocyte, and DLD-l iNOS. Other researchers have noted tissue-dependent transcriptional heterogeneity generated by alternative splicing in cytochrome P-450-related genes:9 including that of neural NOS mRNA.60.h' Likewise, generation of tissue-specific or cell lineage-specific molecular isoforms by alternative splicing of exons in response to environmental stimuli in different cell types (eg, during embryogenesis, or with differentiation of certain For personal use only. on August 30, 2017. by guest www.bloodjournal.org From types, as has been noted with CD44"') might also occur with human iNOS. We continue work to fully explore these possibilities in human monocyte iNOS.
The promoter regions of mouse macrophage iNOS genomic DNA have been partially analyzed and consensus sequences for several known DNA-binding protein promoters have been
The promoter region for the human hepatocyte iNOS genomic DNA has been partially analyzed."' and although the mouse and human iNOS promoter regions were generally similar, some differences were noted. Thus, it is possible that the promoter region in the human mononuclear phagocyte iNOS gene is different from that in the mouse gene, and that human mononuclear phagocytes require different stimuli for activation for high level transcription and subsequent NOS and NO production. Further analysis of the promoter region of the human mononuclear phagocyte iNOS genomic DNA should give important information regarding this possibility.
.. It is clear that humans can be induced to produce increased amounts of NO in vivo with infection and shock," and when receiving IL-2 treatment for can~er.h'.~~ The cells producing the excess NO in vivo in these conditions are not known. Mononuclear phagocytes, hepatocytes, smooth muscle cells, endothelial cells, and/or other cells could be overproducing NO. Based on our findings of only low NO production by stimulated human mononuclear phagocytes in vitro, and undetectable levels of the NOS cofactor tetrahydrobiopterin in freshly isolated and culturedstimulated human mononuclear phagocytes, one could also speculate that humans have evolved to a state in which mononuclear phagocytes do not "need" to produce large amounts of NO in physiologic or pathologic conditions, and that alternate antimicrobial and antitumor effector mechanisms exist in these cells. A full understanding of human mononuclear phagocyte iNOS and the NO production pathway will be valuable in understanding physiology and pathology. Understanding the reason for the relative low level NO production and correcting this relative "deficiency" might provide an important means of increasing the effector function of human mononuclear phagocytes and enhancing host defense against microbes and malignant cells. 
